Current status of chemokine receptor inhibitors in development

Immunology Letters

Volumn 145, Issue 1-2, 2012, Pages 68-78

  Allegretti, Marcello ^a   Cesta, Maria Candida ^a   Garin, Alexandre ^b   Proudfoot, Amanda E I ^b  

^a Chemistry Section   (Italy)

^b MERCK SERONO S A   (Switzerland)

Author keywords

Allosteric inhibitors; CC receptor antagonists; Chemokine; CXC; HIV; Inflammatory diseases

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 [3 [4 (3,4 DICHLOROBENZYL) 2 MORPHOLINYLMETHYL]UREIDOMETHYL]BENZAMIDE; AMG 487; APLAVIROC; AZD 1678; BERTILIMUMAB; BINDARIT; CCX 282; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CP 481715; GSK 1325756; GSK 1605786; INTERLEUKIN 8; MARAVIROC; MLNM 3897; MOGAMULIZUMAB; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NAVARIXIN; PLERIXAFOR; REPARIXIN; SB 656933; SCH 479833; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC DISEASE; ALLERGIC ENCEPHALOMYELITIS; ALLERGIC RHINITIS; ALLERGY; ALLOSTERISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; BREAST CANCER; CELL HYPERPLASIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLITIS; CROHN DISEASE; CYSTIC FIBROSIS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT DYSFUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC DISEASE; INFLAMMATORY PAIN; LIVER DISEASE; LIVER METASTASIS; LIVER TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NEUTROPHILIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; QT PROLONGATION; RECEPTOR BLOCKING; REPERFUSION INJURY; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SKIN INFLAMMATION; T CELL LEUKEMIA;

EID: 84862183490     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.04.003     Document Type: Review

References (138)

1. Loetscher P., Seitz M., Baggiolini M., Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996, 184:569-577.
2. Sica A., Saccani A., Borsatti A., Power C.A., Wells T.N., Luini W., et al. Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J Exp Med 1997, 185:969-974.
3. Kuritzes D.R. HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS 2009, 4:82-87.
4. Steinberg M., Silva M. Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Clin Ther 2010, 32:821-843.
5. Schall T.J., Proudfoot A.E. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 2011, 11:355-363.
6. Cox M.A., Jenh C.H., Gonsiorek W., Fine N., Narula S.K., Zavodny P.J., et al. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotropic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 2001, 59:707-715.
7. Blanpain C., Doranz B.J., Bondue A., Govaerts C., De Leener A., Vassart G., et al. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem 2003, 278:5179-5187.
8. Gonsiorek W., Fan X., Hesk D., Fossetta J., Qiu H., Jakway J., et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 2007, 322:477-485.
9. Bertini R., Allegretti M., Bizzarri C., Moriconi A., Locati M., Zampella G., et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 2004, 101:11791-11796.
10. Sabroe I., Peck M.J., Van Keulen B.J., Jorritsma A., Simmons G., Clapham P.R., et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 2000, 275:25985-25992.
11. Mailman R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007, 28:390-396.
12. Galandrin S., Oligny-Longpré G., Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 2007, 28:423-430.
13. Baker J.G., Hill S.J. Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci 2007, 28:374-381.
14. Gilchrist A. Modulating G-protein-coupled receptors: from traditional pharmacology to allosterics. Trends Pharmacol Sci 2007, 28:431-437.
15. Bosier B., Hermans E. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. Trends Pharmacol Sci 2007, 28:438-446.
16. Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 2007, 28:407-415.
17. Leach K., Sexton P.M., Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive pharmacology. Trends Pharmacol Sci 2007, 28:382-389.
18. Rosenkilde M.M., Benned-Jensen T., Frimurer T.M., Schwartz T.W. The minor binding pocket: a major player in 7TM receptor activation. Trends Pharmacol Sci 2010, 31:567-574.
19. Baggiolini M., Loetscher P. Chemokines in inflammation and immunity. Immunol Today 2000, 21:418-420.
20. Bizzarri C., Beccari A.R., Bertini R., Cavicchia M.R., Giorgini S. Allegretti M ELR+ CXCR chemokines and their receptor (CXC chemokine rceptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 2006, 112:139-149.
21. Ahuja S.K., Murphy P.M. The CXC chemokines growth-related oncogene (Gro)alpha, GRO, beta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 1996, 271:20545-20550.
22. Tani K., Su S.B., Utsunomiya I., Oppenheim J.J., Wang J.M. Interferon-gamma maintains the binding and functional capacity of receptors for IL-8 on cultured human T cells. Eur J Immunol 1998, 28:502-507.
23. Robertson M.J. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002, 71:173-183.
24. Bizzarri C., Allegretti M., Di Bitondo R., Cervellera M.N., Colotta F., Bertini R. Pharmacological inhibition of intereleukin-8 (IL-8) as a new approach for the prevention and treatment of several human diseases. Curr Med Chem Anti Inflamm Anti Allergy Agents 2003, 2:67-79.
25. Brandolini L., Allegretti M., Colagioia S., Novellini R., Colotta F., Bertini R. Update on current and future pharmacologic therapy in COPD. Curr Med Chem Anti Inflamm Anti Allergy Agents 2004, 3:81-101.
26. Russo R.C., Guabiraba R., Garcia C.C., Barcelos L.S., Roffê E., Souza A.L., et al. Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2009, 40:410-421.
27. Russo R.C., Garcia C.C., Teixeira M.M. Anti-inflammatory drug development: broad or specific chemokine receptor antagonists. Curr Opin Drug Discov Devel 2010, 13:414-427.
28. Chapman R.W., Philips J.E., Curran A.K., Lundell D., Fine J.S. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009, 121:55-68.
29. Yang X.D., Corvalan J.R.F., Wang P., Roy C.M.N. Geoffrey Davis C. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999, 66:401-410.
30. Holz O., Khalilieh S., Ludwig-Sengpiel A., Watz H., Stryszak P., Soni P., et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010, 35:564-570.
31. Lazaar A.L., Sweeney L.E., Macdonald A.J., Alexis N.E., Chen C., Tal-Singer R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011, 72:282-293.
32. Marcos V., Zhou Z., Yildrim A.O., Bohla A., Hector A., Vitkov L., et al. CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat Med 2010, 16:1018-1023.
33. Souza D.G., Bertini R., Vieira A.T., Cunha F.Q., Poole S., Allegretti M., et al. Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 2004, 143:132-142.
34. Garau A., Bertini R., Mosca M., Bizzarri C., Anacardio R., Triulzi S., et al. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat. Eur Cytokine Netw 2006, 17:35-41.
35. Cugini D., Azzolini N., Gagliardini E., Cassis P., Bertini R., Colotta F., et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005, 67:1753-1761.
36. Moriconi A., Cesta M.C., Cervellera M.N., Aramini A., Colagioia S., Beccari A.R., et al. Rational design of non-competitive and dual inhibitors of interleukin-8 (IL-8) receptors. J Med Chem 2007, 50:3984-4002.
37. Bertini R., Barcelos L.S., Beccari A.R., Cavalieri B., Moriconi A., Bizzarri C., et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. Br J Pharmacol 2012, 165:436-454.
38. Varney M.L., Singh S., Li A., Mayer-Ezell R., Bond R., Singh R.K. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastasis. Cancer Lett 2011, 300:180-188.
39. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010, 120:485-497.
40. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000, 21:90-113.
41. Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., et al. Chemokine receptor specific for IP10 anf mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996, 184:963-969.
42. Qin S., Rottman J.B., Kassam N., Weinblatt M., Loetscher M., et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998, 101:746-754.
43. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1T helper cells (Th1s) and Th2s. J Exp Med 1998, 187:129-134.
44. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999, 103:807-815.
45. Lacotte S., Brun S., Muller S., Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann NY Acad Sci 2009, 1173:310-317.
46. Mach F., Sauty A., Iarossi A.S., Sukhova G.K., Neote K., Libby P., et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999, 104:1041-1050.
47. Hancock W.W., Lu B., Gao W., Csizmadia V., Faia K., King J.A., et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000, 192:1515-1520.
48. Inston N., Drayson M., Ready A., Cockwell P. Serial changes in the expression of CXCR3 and CCR5 on peripheral blood lymphocytes following human renal transplantation. Exp Clin Transplant 2007, 5:638-642.
49. Yuan Y.H., ten Hove T., The F.O., Slors J.F., van Deventer S.J., te Velde A.A. Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm Bowel Dis 2001, 7:281-286.
50. Tensen C.P., Flier J., Van Der Raaij-Helmer E.M., Sampat-Sardjoepersad S., Van Der Schors R.C., Leurs R., et al. Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol 1999, 112:716-722.
51. Flier J., Boorsma D.M., van Beek P.J., Nieboer C., Stoof T.J., Willemze R., et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001, 194:398-405.
52. Agostini C., Cassatella M., Zambello R., Trentin L., Gasperini S., Perin A., et al. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 1998, 161:6413-6420.
53. Campanella G.S., Tager A.M., El Khoury S.Y., Abrazinski T.A., Manice L.A., et al. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc Natl Acad Sci U S A 2008, 105:4814-4819.
54. Miu J., Mitchell A.J., Müller M., Carter S.L., Manders P.M., McQuillan J.A., et al. Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. J Immunol 2008, 180:1217-1230.
55. Glass W.G., Subbarao K., Murphy B., Murphy P.M. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 2004, 173:4030-4039.
56. Danesh A., Seneviratne C., Cameron C.M., Banner D., Devries M.E., Kelvin A.A., et al. Cloning, expression and characterization of ferret CXCL10. Mol Immunol 2008, 45:1288-1297.
57. Kawada K., Sonoshita M., Sakashita H., Takabayashi A., Yamaoka Y., Manabe T., et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004, 64:4010-4017.
58. Walser T.C., Rifat S., Ma X., Kundu N., Ward C., Goloubeva O., et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006, 66:7701-7707.
59. Kawada K., Hosogi H., Sonoshita M., Sakashita H., Manabe T., Shimahara Y., et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007, 26:4679-4688.
60. Pien H. Presented at the 26th annual JP Morgan healthcare conference 2008.
61. Deurloo D.T., Chaudhary M.N., Olkiewicz K.M., Silva I.A., Choi S.W., Liu C., et al. A small molecular weight antagonists of CXCR3 reduces the severity of experimental idiopathic pneumonia syndrome and improves survival following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:105.
62. Halloran P.F., Fairchild R.L. The puzzling role of CXCR3 and its ligands in organ allograft rejection. Am J Transplant 2008, 8:1578-1579.
63. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382:829-833.
64. Oberlin E., Amara A., Bachjelerie F., Bessia C., Virelezier J.L., Arenzana-Seisdedos F., et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382:833-835.
65. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science 1996, 272:872-877.
66. Boutet A., Salim H., Leclerc P., Tardieu M. Cellular expression of functional chemokine receptors CCR5 and CXCR4 in human embryonic neurons. Neurosci Lett 2001, 311:105-108.
67. Gabuzda D., Wang J. Chemokine receptors and mechanisms of cell death in HIV neuropathogenesis. J Neurovirol 2000, (Suppl. 1):S24-S32.
68. Köller H., Schaal H., Rosenbaum C., Czardybon M., Von Giesen H.J., Müller H.W., et al. Functional CXCR4 receptor development parallels sensitivity to HIV-1 gp120 in cultured rat astroglial cells but not in cultured rat cortical neurons. J Neurovirol 2002, 8:411-419.
69. Mocchetti I., Bachis A. Brain-derived neurotrophic factor activation of TrkB protects neurons from HIV-1/gp120-induced cell death. Crit Rev Neurobiol 2004, 16:51-57.
70. Pandey V., Bolsover S.R. Immediate and neurotoxic effects of HIV protein gp120 act through CXCR4 receptor. Biochem Biophys Res Commun 2000, 274:212-215.
71. Bachis A., Major E.O., Mocchetti I. Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventiong gp120 internalization. J Neurosci 2003, 23:5715-5722.
72. Kaul M., Zheng J., Okamoto S., Gendelman H.E., Lipton S.A. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 2005, 12:878-892.
73. Burger J.A. CXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you. Leuk Res 2009, 33:474-478.
74. Pitchford S.C., Furze R.C., Jones C.P., Wengner A.M., Rankin S.M. Differential mobilization if subsets of progenitor cells from the bone marrow. Cell Stem Cell 2009, 4:62-72.
75. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
76. Kryczek I., Wei S., Keller E., Liu R., Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007, 292:C987-C995.
77. Li T., Li H., Wang Y., Harvard C., Tan J.L., Au A., et al. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol 2011, 223:519-530.
78. Innamorati G., Valenti M.T., Giovinazzo F., Dalle Carbonare L., Parenti M., Bassi C. Molecular approaches to target GPCRs in cancer therapy. Pharmaceuticals 2011, 4:567-589.
79. Wu X., Lee V.C., Chevalier E., Hwang S.T. Chemokine receptors as targets for cancer therapy. Curr Pharm Des 2009, 15:742-757.
80. Wong D., Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 2008, 14:7975-7980.
81. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovic R., Miao Z., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213.
82. Thelen M., Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio?. J Neuroimmunol 2008, 198:9-13.
83. Wang J., Shiozawa Y., Wang J., Wang Y., Jung Y., Pienta K.J., et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008, 283:4283-4294.
84. Neote K., DiGregorio D., Mak J.Y., Horuk R., Schall T.J. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 1993, 72:415-425.
85. Balashov K.E., Rottmen J.B., Weiner H.L., Hancock W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1 alpha and IP10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999, 96:6873-6878.
86. Sørensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999, 103:807-815.
87. Liang M., Rosser M., Ng H.P., May K., Bauman J.G., Islam I., et al. Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. Eur J Pharmacol 2000, 389:41-49.
88. Liang M., Mallari C., Rosser M., Ng H.P., May K., Monahan S., et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000, 275:19000-19008.
89. McColl S.R., Staykova M.A., Wozniak A., Fordham S., Bruce J., Willenborg D.O. Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J Immunol 1998, 161:6421-6426.
90. Bonecchi R., Polentarutti N., Luini W., Borsatti A., Bernasconi S., Locati M., et al. Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils. J Immunol 1999, 162:474-479.
91. Proudfoot A.E., Power C.A., Schwarz M.K. Anti-chemokine small molecule drugs: a promising future. Expert Opin Investig Drugs 2010, 19:345-355.
92. Berahovich R.D., Miao Z., Wang Y., Premack B., Howard M.C., Schall T.J. Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 2005, 174:7341-7351.
93. Dairaghi D.J., Zhang P., Wang Y., Seitz L.C., Johnson D.A., Miao S., et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clin Pharmacol Ther 2011, 89:726-734.
94. Haringman J.J., Kraan M.C., Smeets T.J., Zwinderman K.H., Tak P.P. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:715-721.
95. Hoshino A., Iimura T., Ueha S., Hanada S., Maruoka Y., Mayahara M., et al. Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts. J Biol Chem 2010, 285:28826-28837.
96. Ishida N., Hayashi K., Hattori A., Yogo K., Kimura T., Takeya T. CCR1 acts downstream of NFAT2 in osteoclastogenesis and ehnaces cell migration. J Bone Miner Res 2006, 21:48-57.
97. Vallet S., Raje N., Ishitsuka K., Hideshima T., Podar K., Chhetri S., et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007, 110:3744-3752.
98. Quinones M.P., Ahuja S.K., Jimenez F., Schaefer J., Garavito E., Rao A., et al. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest 2004, 113:856-866.
99. Bruhl H., Cihak J., Schneider M.A., Plachy J., Rupp T., Wenzel I., et al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol 2004, 172:8908.
100. Proudfoot A.E. Is CCR2 the right chemokine receptor to target in rheumatoid arthritis. Arthritis Rheum 2008, 58:1889-1891.
101. Loberg R.D., Day L.L., Harwood J., Ying C., St John L.N., Giles R., et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006, 8:578-586.
102. Roca H., Varsos Z.S., Mizutani K., Pienta K.J. CCL2, surviving and autophagy: new links with implications in human cancer. Autophagy 2008, 4:969-971.
103. Monti P., Leone B.E., Marchesi F., Balzano G., Zerbi A., Scaltrini F., et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003, 63:7451-7461.
104. Zhang J., Patel L., Pienta K.J. CC chemokine ligand (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010, 21:41-48.
105. Goede V., Brogelli L., Ziche M., Augustin H.G. Induction of inflammatory angiogenesis by monocyte chemoattactant protein-1. Int J Cancer 1999, 82:765-770.
106. Li X., Loberg R., Liao J., Ying C., Snyder L.A., Pienta K.J., et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009, 69:1685-1692.
107. Humbles A.A., Lu B., Friends D.S., Okinaga S., Lora J., Al-Garawi A., et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci U S A 2002, 99:1479-1484.
108. Ma W., Bryce P.J., Humbles A.A., Laouini D., Yalcindag A., Alenius H., et al. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002, 109:621-628.
109. Takeda A., Baffi J.Z., Kleinman M.E., Cho W.G., Nozaki M., Yamada K., et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 2009, 460:225-230.
110. Li Y., Huang D., Xia X., Wang Z., Luo L., Wen R. CCR3 and choroidal neovascularization. PLoS One 2011, 6:e17106.
111. Chvatchko Y., Hoogewerf A.J., Meyer A., Alouani S., Juillard P., Buser R., et al. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 2000, 191:1755-1764.
112. Yamamoto K., Utsunomiya A., Tobinai K., Tsukasaki K., Uike N., Uozumi K., et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28:1591-1598.
113. Berger E.A. HIV entra and tropism: the chemokine receptor connection 1997, p. S3-16. 11 ed.
114. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene [see comments]. Nature 1996, 382:722-725.
115. Sellebjerg F., Madsen H.O., Jensen C.V., Jensen J., Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000, 102:98-106.
116. Silversides J.A., Heggarty S.V., McDonnell G.V., Hawkins S.A., Graham C.A. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 2004, 10:149-152.
117. Gade-Andavolu R., Comings D.E., MacMurray J., Rostamkhani M., Cheng L.S., Tourtellotte W.W., et al. Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet Med 2004, 6:126-131.
118. Fischereder M., Luckow B., Hocher B., Wuthrich R.P., Rothenpieler U., Schneeberger H., et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001, 357:1758-1761.
119. Kindberg E., Mickiene A., Ax C., Akerlind B., Vene S., Lindquist L., et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008, 197:266-269.
120. Lim J.K., McDermott D.H., Lisco A., Foster G.A., Krysztof D., Follmann D., et al. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis 2010, 201:178-185.
121. Shahrara S., Proudfoot A.E., Woods J.M., Ruth J.H., Amin M.A., Park C.C., et al. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum 2005, 52:1907-1919.
122. Okamoto H., Kamatani N.A. CCR-5 antagonist inhibits the development of adjuvant arthritis in rats. Rheumatology (Oxford) 2006, 45:230-232.
123. Yang Y.F., Mukai T., Gao P., Yamaguchi N., Ono S., Iwaki H., et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 2002, 32:2124-2132.
124. Vierboom M.P., Zavodny P.J., Chou C.C., Tagat J.R., Pugliese-Sivo C., Strizki J., et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum 2005, 52:627-636.
125. Blanpain C., Wittamer V., Vanderwinden J.M., Boom A., Renneboog B., Lee B., et al. Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways. J Biol Chem 2001, 276:23795-23804.
126. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices if CCR5. Proc Natl Acad Sci U S A 2000, 97:5639-5644.
127. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009, 10:514-523.
128. Comerford I., Bunting M., Fenix K., Haylock-Jacobs S., Litchfield W., Harata-Lee Y., et al. An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation? CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays 2010, 32:1067-1076.
129. Hedrick M.N., Lonsdorf A.S., Shirakawa A.K., Richard-Lee C.C., Liao F., Singh S.P., et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 2009, 119:2317-2329.
130. Elhofy A., Depaolo R.W., Lira S.A., Lukacs N.W., Karpus W.J. Mice deficient for CCR6 fail to control chronic experimental autoimmune enchephalomyelitis. J Neuroimmunol 2009, 213:91-99.
131. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008, 25:345-356.
132. Chung C.D., Kuo F., Kumer J., Motani A.S., Lawrence C.E., Henderson W.R., et al. CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J Immunol 2003, 170:581-587.
133. Chensue S.W., Lukacs N.W., Yang T.Y., Shang X., Frait K.A., Kunkel S.L., et al. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med 2010, 193:573-584.
134. Reiss Y., Proudfoot A.E., Power C.A., Campbell J.J., Butcher E.C. CC chemokine (CCR)4 and the CCR10 ligand cutaneous T cell-attacting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001, 194:1541-1547.
135. Vicari A.P., Figueros D.J., Hedrick J.A., Foster J.S., Singh K.P., Menon S., et al. TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity 1997, 7:291-301.
136. Wurbel M.A., McIntire M.G., Dwyer P., Fiebiger E. CCL25/CCR9 iinteractions regulate large intestinal inflammation in a murine model of acute colitis. PLoS One 2011, 6:e16442.
137. Rivera-Nieves J., Ho J., Bamias G., Ivashkina N., Ley K., Oppermann M., et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006, 131:1518-1529.
138. Keshav S., Johnson D., Bekker P., Schall T.J. PROTECT-1 study demonstrated efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in treatment of patients with moderate-to-severe Crohn's disease. Gastroenterology 2009, 136:A65.